Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite presented as an injection for intravenous and subcutaneous use. By inhibiting dihydrofolate reductase, it reduces DNA synthesis and cell proliferation, making it effective for treating certain cancers, autoimmune disorders such as rheumatoid arthritis and psoriasis, and ectopic pregnancy in adult patients. It is approved for use in the European Union and is available only by prescription.

GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring quality and regulatory compliance.

Methotrexate is used in several disease categories where rapid cell turnover or immune activation is a key factor.

- Rheumatoid arthritis: reduces disease activity and joint inflammation. - Psoriasis: slows skin cell proliferation and improves lesions. - Acute lymphoblastic leukemia: induces remission by targeting rapidly dividing lymphoblasts. - Non-Hodgkin lymphoma: suppresses malignant B‑cell growth. - Osteosarcoma: interferes with tumor cell DNA synthesis. - Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting. - Mouth sores (mucositis). - Fatigue or weakness. - Elevated liver enzymes.

Serious or Rare Side Effects: - Bone marrow suppression leading to anemia, leukopenia, or thrombocytopenia. - Pulmonary toxicity presenting as cough or shortness of breath. - Severe hepatic injury or renal failure.

When using Methofill, several precautions should be observed to minimize risk.

- Pregnancy: contraindicated – avoid use in pregnant women. - Renal function: assess before initiating – dose may need adjustment in impaired kidneys. - Hepatic function: monitor liver enzymes – avoid in severe liver disease. - Hematologic monitoring: regular blood counts – risk of bone marrow suppression. - Drug interactions: avoid concurrent NSAIDs and live vaccines – may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Nonsteroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity, especially renal. - Penicillins (e.g., ampicillin): reduce methotrexate efficacy by competing for renal tubular secretion. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate absorption and increase serum levels. - Allopurinol: can raise methotrexate concentrations, requiring close monitoring.